SAMSUNG BIOLOGICS CO

A207940
End-of-day quote. End-of-day quote  - 11/26
870000KRW +2.72%

Samsung Biologics : S.Korea approves Moderna's COVID-19 vaccine produced by Samsung Biologics

10/25/2021 | 11:31pm

SEOUL, Oct 26 (Reuters) - South Korea granted emergency use approval for Moderna's COVID-19 vaccine produced by South Korean drugmaker Samsung BioLogics, the health ministry said on Tuesday.

Moderna has agreed to distribute 2.44 million doses of the shots produced by Samsung to South Korea after Samsung's COVID-19 vaccine facility on Monday obtained Good Manufacturing Practice (GMP) certification from the drug safety ministry.

Samsung entered into a "fill and finish https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-south-korea-sign-production-deal-mrna-vaccines-2021-05-22 " deal with Moderna in May. This type of contract involves putting vaccines into vials or syringes, sealing them and packaging them up for shipping, but not making the vaccine itself.

The plant has yet to win approval from the U.S. and European regulators to have the shots shipped outside the country, Samsung said.

In May https://www.reuters.com/world/asia-pacific/south-koreas-moon-be-second-leader-second-asian-welcomed-by-biden-2021-05-21, the U.S. President Joe Biden said he and South Korean President Moon Jae-in had agreed on a comprehensive partnership on COVID-19 vaccines.

South Korea said the Moderna shots produced by Samsung will be widely used in the current quarter, including as booster shots for high-risk people. (Reporting by Sangmi Cha; Editing by Lincoln Feast.)

© Reuters 2021
Copier lien
All news about SAMSUNG BIOLOGICS CO.,LTD.
3d ago
4d ago
11/19
11/15
11/15